Charles River Laboratories Intl. Inc vs iShares Semiconductor ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $230.89 (market cap $11.14B), while iShares Semiconductor ETF trades at $549.8. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SOXX | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $233.60 | $655.01 |
52-Week Low | $145.57 | $236.93 |
Enterprise Value | $14.00B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SOXX trades at $553.1, down 4.82% over 24 hours amid a broader semiconductor selloff. Technical indicators show a bearish trend with support at $530 and resistance at $557. The ETF has delivered exceptional YTD performance with 93.3% gains through July 6, 2026, driven by AI demand, though recent volatility has erased some gains. A dividend of $0.28 is scheduled for June 2026.
Outlook remains mixed with strong AI-driven growth potential offset by sector volatility and Michael Burry's bearish bet. Key risks include semiconductor cyclicality and geopolitical tensions. The ETF offers diversified exposure to leading chip companies but faces near-term pressure from the recent correction.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →